About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.

Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...

Gladstone Institutional Advisory LLC lifted its position in Veru Inc. (NASDAQ:VERU – Free Report) by 52.7% in the 4th quarter, according to the company in its most recent filing with the Securities ...

Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...

Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation ...